Venn 1995.
Study characteristics | ||
Methods |
Study design: prospective, randomized study Study dates: not reported Setting: outpatient, multicenter, national Country: United Kingdom |
|
Participants |
Inclusion criteria: men with:
Exclusion criteria: not reported Total number of participants randomized: 96 Group 1: n = 48 Transurethral microwave Hyperthermia
* no SD or 95% CI reported Group 2: n = 48 transurethral sham
* no SD or 95% CI reported |
|
Interventions |
Group 1 (n = 48) TUMT Participants in the treated group underwent 1 hr of microwave hyperthermia, with a maximum urethral temperature of 46 °C or a maximum rectal temperature of 42.5 °C. The machine was designed and constructed in conjunction with Microwave Engineering Designs, Newport, Isle of Wight, UK (434 MHz, maximum power of 50 W). The antenna was a helical coil, loaded in a modified eyeless 22F Foley Simplastic catheter fitted with water cooling Group 2 (n = 48) Sham Treated with the same procedure but without the use of heat Co‐interventions: After selection for inclusion in the trial a treatment catheter was inserted under antibiotic cover (gentamicin 80 mg) |
|
Outcomes |
Urologic symptom scores How measured: AUA scores (percentage of improvement). Madsen score response rate (responders as those with a score < 8) Time points measured: baseline,3 and 6 months Time points reported: baseline,3 and 6 months (responder data only at 3 months) Subgroups: none Relevant outcomes not reported in this study
|
|
Funding sources | Not available | |
Declarations of interest | Not available | |
Notes | Participants were selected from waiting lists for transurethral resection of the prostate (TURP) at St Thomas's Hospital and Worthing Hospital, or by direct referral. Cross‐over: after 3 months, 47 participants in the treated group and 46 of the controls were assessed. After 6 months, 42 treated participants and 20 control participants were assessed, because 24 participants in the control group had been made aware of the sham treatment and so were not included in the analysis Protocol: not available Language of publication: English |
|
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Random sequence generation (selection bias) | Low risk | Comment: The investigators describe a random component in the sequence generation process. Quote: “patients were then randomly assigned to either a treated or control group by selection of sealed envelopes prepared before the trial.” |
Allocation concealment (selection bias) | Unclear risk | Comment: Participants and investigators enrolling participants could not foresee assignment, although it is not clear if the envelopes were opaque. Quote: “patients were then randomly assigned to either a treated or control group by selection of sealed envelopes prepared before the trial.” |
Blinding of participants and personnel (performance bias) All outcomes | Unclear risk | Comment: It is unclear if personnel was blinded (first 3 months). Quote: “The patients were not aware of the group to which they were assigned.” |
Blinding of outcome assessment (detection bias) Objective outcomes | Low risk | Comment: These outcomes are unlikely to be affected by blinding. Quote: “The patients were not aware of the group to which they were assigned.” |
Blinding of outcome assessment (detection bias) Subjective outcomes | Low risk | Comment: These outcomes are likely to be affected by blinding. Quote: “The patients were not aware of the group to which they were assigned.” |
Incomplete outcome data (attrition bias) All outcomes | Low risk | All outcomes: outcome data was available for nearly all participants. After 3 months, 47/48 patients in the treated group and 46/48 of the controls were assessed (6‐month data not included in this review, see “Notes”) |
Selective reporting (reporting bias) | Unclear risk | No protocol available. Insufficient information to permit judgment of ‘Low risk’ or ‘High risk’. |
Other bias | Low risk | No other sources of bias were identified |